Skip to main content
SpringerLink
Log in

Guidelines for Monitoring Patients Taking Tamoxifen Treatment

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Tamoxifen is the most important anti—breast cancer drug in clinical use and has the potential to be used as a chemopreventive breast cancer agent. Using outpatient hysteroscopy and based on 2 case control and 2 cohort follow-up studies in our department, we were able to demonstrate that 50% of women receiving long term tamoxifen experienced some sort of adverse endometrial effects. Although many women retain an atrophic endometrial layer, tamoxifen intake can lead to extensive senile cystic atrophia of the human endometrium, to endometrial hyperplasia and to endometrial polyp formation. Based on a critical review of the literature, we have shown that tamoxifen doubles the risk for developing endometrial cancer in postmenopausal women, although this increased risk may be higher and is duration (i.e. time of use)-dependent.

Screening patients with breast cancer for endometrial abnormalities while they are taking tamoxifen is feasible and uterine morbidity related to tamoxifen intake is preventable. Although screening may increase drug compliance it may not be cost-beneficial. However, uterine safety becomes important when only a small benefit of the treatment is to be expected as in the use of tamoxifen in healthy women for breast cancer prevention.

The aim of this report is to discuss methods and guidelines for detecting endometrial adverse effects of tamoxifen and to provide the clinician with a current opinion on timing and frequency of screening patients taking tamoxifen for the development of endometrial cancer.

In summary, those who advocate screening should start with pretreatment uterine assessment using transvaginal ultrasonography or outpatient hysteroscopy. Symptom-free women with a normal pretreatment uterine cavity can be screened annually with transvaginal sonography from 2 to 3 years after the start of tamoxifen. Hysteroscopy or saline infusion sonography will be required if there is endometrial thickening because the only value of transvaginal ultrasonography is a normal finding being a thin rectilinear endometrium.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Murray WS. Ovarian secretion and tumor incidence. Science 1927; 66: 600–1

    Article  PubMed  CAS  Google Scholar 

  2. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; II: 104–7, 162-5

    Article  Google Scholar 

  3. Walpole AL, Patterson E. Synthetic oestrogens in mammary cancer. Lancet 1949; II: 783–6

    Article  Google Scholar 

  4. Harper MJ, Walpole AL. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 1966; 212: 87

    Article  PubMed  CAS  Google Scholar 

  5. Toft D, Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterisation. Proc Natl Acad Sci USA 1966; 55: 1574–81

    Article  PubMed  CAS  Google Scholar 

  6. Early Breast Cancer Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451–67

    Google Scholar 

  7. McDonnell DP. The molecular pharmacology of SERMs: trends in endocrinology and metabolism. 1999; 10: 301–11

    Article  PubMed  CAS  Google Scholar 

  8. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–6

    Article  PubMed  CAS  Google Scholar 

  9. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86: 1534–9

    Article  PubMed  CAS  Google Scholar 

  10. Fisher B, Wickerman DL, Costantino JC, et al. Tamoxifen for prevention of breast cancer: report of the NSABP-P1 study. J Natl Cancer Inst 1998; 90: 1371–83

    Article  PubMed  CAS  Google Scholar 

  11. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93–7

    PubMed  CAS  Google Scholar 

  12. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98–101

    PubMed  CAS  Google Scholar 

  13. Neven P, De Muylder X, Van Belle Y, et al. Tamoxifen and the uterus and endometrium. Lancet 1989; I: 375–6

    Article  Google Scholar 

  14. Assikis VJ, Neven P, Jordan VC, et al. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996; 32A: 1464–76

    Article  PubMed  CAS  Google Scholar 

  15. Fornander T, Cedermark B, Mattsson A, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; II: 117–20

    Article  Google Scholar 

  16. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83: 1013–7

    Article  PubMed  CAS  Google Scholar 

  17. Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project B-14. J Natl Cancer Inst 1994; 86: 527–37

    Article  PubMed  CAS  Google Scholar 

  18. Some pharmaceutical drugs. IARC monographs on the evaluation of carcinogenic risks to humans, vol 66. Lyon: International Agency for Research on Cancer, 1996

  19. Baum M. Tamoxifen and the breast. Eur J Cancer 1998; 34: S7–8

    Article  Google Scholar 

  20. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994; 343: 1318–21

    Article  PubMed  CAS  Google Scholar 

  21. Neven P, De Muylder X, Van Belle Y, et al. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynaecol Rep Biol 1990; 35: 235–8

    Article  CAS  Google Scholar 

  22. Mourits MJE, Van der Zee AGJ, et al. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 1999; 73: 21–6

    Article  PubMed  CAS  Google Scholar 

  23. Neven P, Vergote I. Controversies regarding tamoxifen and uterine carcinoma. Curr Opin Obstet Gynecol 1998; 10(1): 9–14

    Article  PubMed  CAS  Google Scholar 

  24. Creasman WT. Endometrial cancer: incidence, prognostic factors, diagnosis and treatment. Semin Oncol 1997; 24: S1140–50

    Google Scholar 

  25. Barakat RR, Wong G, Curtin JP, et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994; 55: 164–8

    Article  PubMed  CAS  Google Scholar 

  26. Barakat RR. Screening for endometrial cancer in patients receiving tamoxifen for breast cancer [editorial]. J Clin Oncol 1999; 17: 1967–8

    PubMed  CAS  Google Scholar 

  27. Love CDB, Muir BB, Scrimgeour JB, et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17: 2050–4

    PubMed  CAS  Google Scholar 

  28. Powles TJ, Bourne T, Athanasiou S, et al. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. Br J Cancer 1998; 78(2): 272–5

    Article  PubMed  CAS  Google Scholar 

  29. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189–97

    Article  PubMed  CAS  Google Scholar 

  30. Berliere M, Charles A, Galant C, et al. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998; 91: 45–50

    Article  Google Scholar 

  31. Ramondetta LM, Sherwood JB, Dunton CJ, et al. Endometrial cancer in polyps associated with tamoxifen use. Am J Obstet Gynecol 1999; 180: 340–1

    Article  PubMed  CAS  Google Scholar 

  32. Langer RD, Pierce JJ, O’Hanlan KA, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 1997; 337: 1792–8

    Article  PubMed  CAS  Google Scholar 

  33. Perrot N, Guyot B, Antoine M, et al. The effects of tamoxifen on the endometrium. Ultrasound Obstet Gynecol 1994; 4: 83–4

    Article  PubMed  CAS  Google Scholar 

  34. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170: 447–51

    PubMed  CAS  Google Scholar 

  35. Cecchini S, Ciatto S, Bonardi R, et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol 1996; 60: 409–11

    Article  PubMed  CAS  Google Scholar 

  36. Tepper R, Beyth Y, Altaras MM, et al. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 1997; 64: 386–91

    Article  PubMed  CAS  Google Scholar 

  37. Lindahl B, Andolf E, Ingvar C, et al. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen. Anticancer Res 1997; 17: 3821–4

    PubMed  CAS  Google Scholar 

  38. Kontostolis E, Stefanidis K, Navrozoglou I, et al. The effects of tamoxifen on the endometrium, blood flow of the uterine arteries and serum lipoprotein (a) levels in postmenopausal women. Gynecol Endocrinol 1998; 12: 185–9

    Article  PubMed  CAS  Google Scholar 

  39. McGonigle KF, Shaw SL, Vasilev SA, et al. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 1998; 178: 1145–50

    Article  PubMed  CAS  Google Scholar 

  40. Fotiou S, Tserkezoglou A, Hadjieleftheriou G, et al. Tamoxifen associated uterine pathology in breast cancer patients with abnormal bleeding. Anticancer Res 1998; 18: 625–9

    PubMed  CAS  Google Scholar 

  41. Randolph J, Ying Y, Maier D. Comparison of real time ultrasonography, hystrosalpingography and laparoscopy/hysteroscopy in the evaluation of uterine abnormalities and tubal patency. Fertil Steril 1986; 46: 828–32

    PubMed  Google Scholar 

  42. Parsons A, Lense J. Sonohysterography for endometrial abnormalities: preliminary results. J Clin Ultrasound 1993; 21: 87–95

    Article  PubMed  CAS  Google Scholar 

  43. Timmerman D, Deprest J, Bourne TH, et al. A randomised trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in tamoxifen-treated postmenopausal breast cancer patients. Am J Obstet Gynecol 1998; 179: 62–70

    Article  PubMed  CAS  Google Scholar 

  44. Achiron R, Lipitz S, Sivan E, et al. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Ultrasound Obstet Gynecol 1995; 6: 116–20

    Article  PubMed  CAS  Google Scholar 

  45. De Muylder X, Neven P, De Somer M, et al. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Obstet 1991; 36: 127–30

    Article  Google Scholar 

  46. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol 1991; 9: 1740–8

    PubMed  CAS  Google Scholar 

  47. van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448–52

    Article  PubMed  Google Scholar 

  48. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91: 1654–60

    Article  PubMed  CAS  Google Scholar 

  49. Neven P, De Muylder X, Van Belle Y, et al. Longitudinal hysteroscopic follow-up during tamoxifen treatment [research paper]. Lancet 1998; 351: 36

    Article  PubMed  CAS  Google Scholar 

  50. Berliere M, Charles A, Galant C, et al. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998; 91: 40–4

    Article  PubMed  CAS  Google Scholar 

  51. Chang J, Powles TJ, Ashley SE, et al. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat 1998; 48(1): 81–5

    Article  PubMed  CAS  Google Scholar 

  52. Neven P, Vergote I. Should tamoxifen users be screened for endometrial lesions? Lancet 1998; 351: 155–7

    Article  PubMed  CAS  Google Scholar 

  53. Vergote I, Neven P. Tamoxifen and the uterus [editorial]. Eur J Cancer 1998; 34Suppl. 4: S1–67

    Article  PubMed  Google Scholar 

  54. Schwartz LB, Snyder J, Horan C, et al. The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifen. Ultrasound Obstet Gynecol 1998; 11: 48–53

    Article  PubMed  CAS  Google Scholar 

  55. ACOG-Committee Opinion. Tamoxifen and endometrial cancer. Number 169, February 1996. Committee on gynecologic practice. American College of Obstetrics and Gynecologists. Int J Gynecol Obstet 1996; 53: 197–9

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department Obstetrics and Gynaecology, Algemene Kliniek St.-Jan, Broekstraat 114, B-1000, Brussels, Belgium

    Patrick Neven & Hilde Vernaeve

Authors
  1. Patrick Neven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hilde Vernaeve
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neven, P., Vernaeve, H. Guidelines for Monitoring Patients Taking Tamoxifen Treatment. Drug-Safety 22, 1–11 (2000). https://doi.org/10.2165/00002018-200022010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200022010-00001

Keywords

Search

Navigation